Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients

BACKGROUND: The CALYPSO phase III trial compared CD (carboplatin-pegylated liposomal doxorubicin (PLD)) with CP (carboplatin-paclitaxel) in patients with platinum-sensitive recurrent ovarian cancer (ROC). Overall survival (OS) data are now mature. METHODS: Women with ROC relapsing >6 months after...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Wagner, U, Marth, C, Largillier, R, Kaern, J, Brown, C, Heywood, M, Bonaventura, T, Vergote, I, Piccirillo, M C, Fossati, R, Gebski, V, Lauraine, E P
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2012
Предметы:
Clinical Study
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3419956/
https://ncbi.nlm.nih.gov/pubmed/22836511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.307
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы